+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Blood Cancer Drugs Market Share, Size, Trends, Industry Analysis Report, By Blood Cancer Type; By Drugs, By Treatment Type; By Region; Segment Forecast, 2021 - 2028

  • PDF Icon

    Report

  • 119 Pages
  • June 2021
  • Region: Global
  • Polaris Market Research
  • ID: 5396998
The global blood cancer drugs market size is expected to reach USD 89.91 billion by 2028 according to this new study. The report “Blood Cancer Drugs Market Share, Size, Trends, Industry Analysis Report, By Blood Cancer Type (Lymphoma, Leukemia, Myeloma); By Drugs, By Treatment Type; By Region; Segment Forecast, 2021-2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.



Federal government funding for research has also led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancements in research, more patients affected with the disease are being diagnosed at appropriate stages and successfully treated. The increasing investment in research is expected to boost growth in this market during forecast period.

The prognosis and treatment for leukemia depend on whether it is acute or chronic and the type of blood cell that is affected. The leukemia market is segmented into acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia.

VELCADE (bortezomib) is a type of chemotherapy drug known as a targeted therapy. It is FDA approved drug for the treatment of mantle cell lymphoma and multiple myeloma. VELCADE has been widely used for number of clinical trials. As a part of clinical trials this drug has been studied in a wide range of individual, including diabetes and renal impairment. VELCADE works by slowing down and/or blocking the action of proteasomes in the cells.

Some of the drugs used to treat multiple myeloma are thalidomide (Thalomid), bortezomib (Velcade), lenalidomide (Revlimid) and corticosteroids (dexamethasone, prednisone). Though chemotherapy kills rapidly growing cancer cells, it may also destroy normal fast-growing cells such as GI tract, bone marrow, hair and mouth. Chemotherapy for leukemia may also affect the ability of bone marrow to produce sufficient number of blood cells.

North America is expected to dominate the global market over the forecast period, this is mainly due to the technological advancement, well-established healthcare infrastructure, accessibility of better treatments which has facilitated the growth of the market in this region. Also, the disease is the third most cause of deaths after lung and colon in North America, which provides as major market growth opportunity for blood cancer drugs.

The incidence rate of blood cancer in UK is 66 in every 100,000. The disease is more prevalent in males with age group between 50 and above. Another organization, the National Institute for Health and Care Excellence. provide guidelines to healthcare professionals for diagnosing the disease in children, young and adults. The organization aims to improve the healthcare facilities with better and enhanced results of diagnostics.

Key market players in the market are Amgen Inc, Johnson & Johnson Inc, Bayer AG., Eli Lily & Co, Pfizer Inc, AstraZeneca, AbbVie Inc, Celgene Corporation, Roche Holding AG, Merck and Company, GlaxoSmithKline Pharmaceuticals Ltd, and Novartis AG.

The publisher has segmented the blood cancer drugs market report on the basis of blood cancer type, drugs, treatment type, and region:


Blood Cancer Drugs by Blood Cancer Type Outlook (Revenue-USD Million, 2016-2028)


  • Lymphoma
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • B-cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt Lymphoma
  • Central Nervous System Lymphoma
  • T-cell Lymphoma
  • Precursor T-Lymphoblastic Lymphoma
  • Peripheral T-Lymphoma
  • Leukemia
  • Acute Myeloid Leukemia
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphocytic Leukemia
  • Myeloma

Blood Cancer Drugs by Drugs Outlook (Revenue-USD Million, 2016-2028)


  • Rituaxan/Mabthera (Rituximab)
  • Gleevac/Glivec (Imatinib)
  • Revlimid (Lenalidomide)
  • Velcade (Bortezomib)
  • Tasigna (Nilotinib)
  • Pomalyst (Pomalidomide)
  • Vidaza (Azacitidine)
  • Kyprolis (Carfilzomib)
  • Adcetris (Brentuximab Vedotin)
  • Others

Blood Cancer Drugs by Treatment Type Outlook (Revenue-USD Million, 2016-2028)


  • Chemotherapeutic
  • mAbs/Targeted Therapies
  • Immunotherapeutic

Blood Cancer Drugs by Regional Outlook (Revenue-USD Million, 2016-2028)


  • North America
  • U.S
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Asia Pacific
  • China
  • India
  • Japan
  • Latin America
  • Brazil
  • Middle East & Africa
Frequently Asked Questions about the Blood Cancer Drugs Market

What is the estimated value of the Blood Cancer Drugs Market?

The Blood Cancer Drugs Market was estimated to be valued at $41.48 Billion in 2021.

What is the growth rate of the Blood Cancer Drugs Market?

The growth rate of the Blood Cancer Drugs Market is 10.9%, with an estimated value of $89.91 Billion by 2028.

What is the forecasted size of the Blood Cancer Drugs Market?

The Blood Cancer Drugs Market is estimated to be worth $89.91 Billion by 2028.

Who are the key companies in the Blood Cancer Drugs Market?

Key companies in the Blood Cancer Drugs Market include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Roche Holding AG and Merck and Company.

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope and Assumptions
1.3. List of Data Sources
2. Executive Summary
3. Market Insights & Analysis
3.1. Market Segmentation: Blood Cancer Drugs Market
3.2. Blood Cancer Drugs - Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing Incidence of Blood Cancer
3.2.1.2. Continual Investment for Cancer Research
3.2.1.3. Robust Product Pipeline
3.2.2. Market restraint analysis
3.2.2.1. Policies Related to Reimbursement
3.2.2.2. Capital Investment
3.3. Industry Analysis - Porter’s
3.4. Industry Analysis - PPEST
3.5. Blood Cancer Drugs Market - Penetration & Growth Prospect Mapping (Types of Leukemia)
3.6. Company Heat map Analysis
3.7. Company Market Share Analysis
4. Blood cancer drugs market Size and Forecast, 2016-2028 by Blood Cancer Type
4.1. Key Findings
4.2. Lymphoma
4.2.1. Hodgkin Lymphoma
4.2.2. Non-Hodgkin Lymphoma
4.2.2.1. B-cell Lymphoma
4.2.2.1.1. Diffuse Large B-Cell Lymphoma
4.2.2.1.2. Mantle Cell Lymphoma
4.2.2.1.3. Burkitt Lymphoma
4.2.2.1.4. Central Nervous System Lymphoma
4.2.2.2. T-cell Lymphoma
4.2.2.2.1. Precursor T-Lymphoblastic Lymphoma
4.2.2.2.2. Peripheral T-Lymphoma
4.2.3. Leukemia
4.2.3.1. Acute Myeloid Leukemia
4.2.3.2. Chronic Myeloid Leukemia
4.2.3.3. Acute Lymphoblastic Leukemia
4.2.3.4. Chronic Lymphocytic Leukemia
4.2.4. Myeloma
5. Blood cancer drugs market Size and Forecast, 2016-2028 by Drugs
5.1. Rituaxan/Mabthera (Rituximab)
5.2. Gleevac/Glivec (Imatinib)
5.3. Revlimid (Lenalidomide)
5.4. Velcade (Bortezomib)
5.5. Tasigna (Nilotinib)
5.6. Pomalyst (Pomalidomide)
5.7. Vidaza (Azacitidine)
5.8. Kyprolis (Carfilzomib)
5.9. Adcetris (Brentuximab Vedotin)
5.10. Others
6. Blood cancer drugs market Size and Forecast, 2016-2028 by Treatment Approaches
6.1. Key Findings
6.2. Chemotherapeutic
6.3. mAbs/Targeted Therapies
6.4. Immunotherapeutic
7. Blood cancer drugs market Size and Forecast, 2016-2028 by Region
7.1. Key Findings
7.2. North America
7.2.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.2.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.2.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.2.4. U.S.
7.2.4.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.2.4.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.2.4.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.2.5. Canada
7.2.5.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.2.5.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.2.5.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.3. Europe
7.3.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.3.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.3.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.3.4. UK
7.3.4.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.3.4.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.3.4.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.3.5. Germany
7.3.5.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.3.5.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.3.5.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.3.6. France
7.3.6.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.3.6.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.3.6.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.4. Asia-Pacific
7.4.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.4.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.4.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.4.4. China
7.4.4.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.4.4.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.4.4.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.4.5. Japan
7.4.5.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.4.5.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.4.5.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.4.6. India
7.4.6.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.4.6.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.4.6.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.5. Latin America
7.5.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.5.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.5.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.5.4. Brazil
7.5.4.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.5.4.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.5.4.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.5.5. Mexico
7.5.5.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.5.5.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.5.5.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
7.6. Middle East & Africa
7.6.1. Blood Cancer Drugs Market by blood cancer type, 2016 - 2028
7.6.2. Blood Cancer Drugs Market by drugs, 2016 - 2028
7.6.3. Blood Cancer Drugs Market by treatment approach, 2016 - 2028
8. Company Profiles
8.1. Johnson & Johnson Inc.
8.1.1. Overview
8.1.2. Financials
8.1.3. Product Benchmarking
8.1.4. Recent Developments
8.2. Amgen Inc.
8.2.1. Overview
8.2.2. Financials
8.2.3. Product Benchmarking
8.2.4. Recent Developments
8.3. Bayer AG.
8.3.1. Overview
8.3.2. Financials
8.3.3. Product Benchmarking
8.3.4. Recent Developments
8.4. Pfizer Inc.
8.4.1. Overview
8.4.2. Financials
8.4.3. Product Benchmarking
8.4.4. Recent Developments
8.5. Eli Lily & Co.
8.5.1. Overview
8.5.2. Financials
8.5.3. Product Benchmarking
8.5.4. Recent Developments
8.6. AstraZeneca
8.6.1. Overview
8.6.2. Financials
8.6.3. Product Benchmarking
8.6.4. Recent Developments
8.7. AbbVie Inc.
8.7.1. Overview
8.7.2. Financials
8.7.3. Product Benchmarking
8.7.4. Recent Developments
8.8. Roche Holding AG
8.8.1. Overview
8.8.2. Financials
8.8.3. Product Benchmarking
8.8.4. Recent Developments
8.9. Celgene Corporation.
8.9.1. Overview
8.9.2. Financials
8.9.3. Product Benchmarking
8.9.4. Recent Developments
8.10. Merck and Company
8.10.1. Overview
8.10.2. Financials
8.10.3. Product Benchmarking
8.10.4. Recent Developments
8.11. Novartis AG.
8.11.1. Overview
8.11.2. Financials
8.11.3. Product Benchmarking
8.11.4. Recent Developments
8.12. GlaxoSmithKline Pharmaceuticals Ltd.
8.12.1. Overview
8.12.2. Financials
8.12.3. Product Benchmarking
8.12.4. Recent Developments
List of Tables
Table 1 Blood Cancer Drugs - Key Market Driver Impact
Table 2 Blood Cancer Drugs Market– Key Market Restraint Impact
Table 3 Global blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 4 Global lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 5 Global non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 6 Global B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 7 Global T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 8 Global leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 9 Global blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 10 Global blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 11 North America blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 12 North America lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 13 North America non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 14 North America B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 15 North America T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 16 Global leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 17 North America blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 18 North America blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 19 U.S. blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 20 U.S. lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 21 U.S. non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 22 U.S. B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 23 U.S. T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 24 U.S. leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 25 U.S. blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 26 U.S. blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 27 Canada blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 28 Canada lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 29 Canada non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 30 Canada B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 31 Canada T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 32 Canada leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 33 Canada blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 34 Canada blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 35 Europe blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 36 Europe lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 37 Europe non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 38 Europe B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 39 Europe T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 40 Europe leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 41 Europe blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 42 Europe blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 43 UK blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 44 UK lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 45 UK non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 46 UK B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 47 UK T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 48 UK leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 49 UK blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 50 UK blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 51 Germany blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 52 Germany lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 53 Germany non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 54 Germany B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 55 Germany T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 56 Germany leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 57 Germany blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 58 Germany blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 59 France blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 60 France lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 61 France non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 62 France B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 63 France T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 64 France leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 65 France blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 66 France blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 67 APAC blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 68 APAC lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 69 APAC non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 70 APAC B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 71 APAC T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 72 APAC leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 73 APAC blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 74 APAC blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 75 China blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 76 China lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 77 China non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 78 China B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 79 China T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 80 China leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 81 China blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 82 China blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 83 India blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 84 India lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 85 India non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 86 India B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 87 India T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 88 India leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 89 India blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 90 India blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 91 Japan blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 92 Japan lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 93 Japan non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 94 Japan B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 95 Japan T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 96 Japan leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 97 Japan blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 98 Japan blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 99 Latin America blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 100 Latin America lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 101 Latin America non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 102 Latin America B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 103 Latin America T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 104 Latin America leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 105 Latin America blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 106 Latin America blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 107 Brazil blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 108 Brazil lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 109 Brazil non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 110 Brazil B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 111 Brazil T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 112 Brazil leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 113 Brazil blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 114 Brazil blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 115 Mexico blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 116 Mexico lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 117 Mexico non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 118 Mexico B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 119 Mexico T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 120 Mexico leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 121 Mexico blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 122 Mexico blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
Table 123 MEA blood cancer drugs market estimates and forecasts, by blood cancer type, 2016 - 2028 (USD Million)
Table 124 MEA lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 125 MEA non-Hodgkin lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 126 MEA B-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 127 MEA T-cell lymphoma drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 128 MEA leukemia drugs market estimates and forecast, by type, 2016 - 2028 (USD Million)
Table 129 MEA blood cancer drugs market estimates and forecasts, by drug type, 2016 - 2028 (USD Million)
Table 130 MEA blood cancer drugs market estimates and forecast, by treatment approaches, 2016 - 2028 (USD Million)
List of Figures
Figure 1. Blood Cancer Drugs Market Segmentation
Figure 2. Estimated Blood Cancer Cases in U.S. - 2019
Figure 3. Blood Cancer Drugs Industry: Porter’s Analysis
Figure 4. Blood Cancer Drugs Market - PEST Analysis
Figure 5. Blood Cancer Drugs Market - PEST Analysis
Figure 6. Heat map analysis
Figure 7. Company market share split (%), 2020
Figure 8. Blood cancer drugs market shares for 2020 & 2028, by blood cancer type (Revenue %)
Figure 9. Blood cancer drugs market shares for 2020 & 2028, by drug type (Revenue %)
Figure 10. Blood cancer drugs market shares for 2020 & 2028, by treatment approaches (Revenue %)
Figure 11. Blood cancer drugs market shares for 2020 & 2028, by region (Revenue %)

Companies Mentioned

  • Johnson & Johnson Inc.
  • Amgen Inc.
  • Bayer AG.
  • Pfizer Inc.
  • Eli Lily & Co.
  • AstraZeneca
  • AbbVie Inc.
  • Roche Holding AG
  • Celgene Corporation
  • Merck and Company
  • Novartis AG
  • GlaxoSmithKline Pharmaceuticals Ltd.